293 related articles for article (PubMed ID: 23591718)
1. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
[TBL] [Abstract][Full Text] [Related]
2. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
Moldt B; Shibata-Koyama M; Rakasz EG; Schultz N; Kanda Y; Dunlop DC; Finstad SL; Jin C; Landucci G; Alpert MD; Dugast AS; Parren PW; Nimmerjahn F; Evans DT; Alter G; Forthal DN; Schmitz JE; Iida S; Poignard P; Watkins DI; Hessell AJ; Burton DR
J Virol; 2012 Jun; 86(11):6189-96. PubMed ID: 22457527
[TBL] [Abstract][Full Text] [Related]
3. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
4. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
[TBL] [Abstract][Full Text] [Related]
5. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
7. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
[TBL] [Abstract][Full Text] [Related]
8. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
[TBL] [Abstract][Full Text] [Related]
9. Fc receptor-mediated antiviral antibodies.
Forthal DN; Moog C
Curr Opin HIV AIDS; 2009 Sep; 4(5):388-93. PubMed ID: 20048702
[TBL] [Abstract][Full Text] [Related]
10. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
Gautam R; Nishimura Y; Pegu A; Nason MC; Klein F; Gazumyan A; Golijanin J; Buckler-White A; Sadjadpour R; Wang K; Mankoff Z; Schmidt SD; Lifson JD; Mascola JR; Nussenzweig MC; Martin MA
Nature; 2016 May; 533(7601):105-109. PubMed ID: 27120156
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.
Klein K; Veazey RS; Warrier R; Hraber P; Doyle-Meyers LA; Buffa V; Liao HX; Haynes BF; Shaw GM; Shattock RJ
J Virol; 2013 Nov; 87(21):11604-16. PubMed ID: 23966410
[TBL] [Abstract][Full Text] [Related]
12. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
13. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.
Forthal DN; Gach JS; Landucci G; Jez J; Strasser R; Kunert R; Steinkellner H
J Immunol; 2010 Dec; 185(11):6876-82. PubMed ID: 21041724
[TBL] [Abstract][Full Text] [Related]
14. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.
Sholukh AM; Watkins JD; Vyas HK; Gupta S; Lakhashe SK; Thorat S; Zhou M; Hemashettar G; Bachler BC; Forthal DN; Villinger F; Sattentau QJ; Weiss RA; Agatic G; Corti D; Lanzavecchia A; Heeney JL; Ruprecht RM
Vaccine; 2015 Apr; 33(17):2086-95. PubMed ID: 25769884
[TBL] [Abstract][Full Text] [Related]
15. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
16. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
[TBL] [Abstract][Full Text] [Related]
17. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
18. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
[TBL] [Abstract][Full Text] [Related]
20. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]